圣诺生物(688117.SH)：预计前三季度净利润同比增加100.53%至145.1%

Core Viewpoint - Shengnuo Biotech (688117.SH) is expected to achieve significant growth in net profit for the first three quarters of 2025, indicating strong business performance and market competitiveness [1] Financial Performance - The company anticipates a net profit attributable to shareholders of approximately 114.20 million to 139.57 million yuan for the first three quarters of 2025, representing an increase of 57.25 million to 82.63 million yuan compared to the same period last year, which is a year-on-year growth of 100.53% to 145.10% [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 113.35 million and 138.54 million yuan, with an increase of 59.70 million to 84.89 million yuan year-on-year, translating to a growth rate of 111.26% to 158.21% [1] Business Development - The company's main business is steadily developing, with increasing demand for its peptide raw material business orders, contributing to overall performance improvement [1] - The continuous implementation of production capacity investments is driving the company's strong market competitiveness and sustained profitability [1]